Diamond Member Pelican Press 0 Posted May 12, 2025 Diamond Member Share Posted May 12, 2025 This is the hidden content, please Sign In or Sign Up JPMorgan says buy this pharmaceutical stock following cost-reduction announcement JPMorgan moved off the sidelines on Teva Pharmaceuticals , citing its cost-cutting efforts. Analyst Chris Schott upgraded U.S.-listed shares of the Israeli pharmaceutical company to overweight from neutral. Schott hiked his price target by $2 to $23, which suggests 35.9% upside from last week’s closing level. Schott’s call comes after the company last week announced a plan for around $700 million in net savings. With that, the company should be able to see an operating margin of 30% in 2027. “Teva’s margin trajectory in 2026/27 had been our primary concern on the story,” Schott wrote to clients in a Monday note. “However, TEVA’s $700mm cost-cut program … bridges much of the gap from current results to the company’s 30% operating margin target by 2027. And looking beyond this cost program, we see TEVA growth improving significantly as we look out to 2027 and beyond.” The announcement comes as Teva shifts to the “acceleration” portion of its “pivot to growth” strategy that was announced in 2023. On top of the efficiency work, Schott called the company’s portfolio “well-positioned” to see growth over time. He specifically noted that the Austedo tablets have surpassed expectations, while olanzapine can become a $1 billion to $2 billion product following its launch slated for next year. With the upgrade, Schott joined the majority of Wall Street analysts who have buy-equivalent ratings, per LSEG. Yet shares tumbled around 5% in Monday’s premarket trading after President Donald Trump announced an executive order that would slash drug costs. The stock has already dropped more than 23% in 2025, reversing course after soaring more than 110% in the prior year. TEVA 1Y mountain TEVA, 1-year This is the hidden content, please Sign In or Sign Up #JPMorgan #buy #pharmaceutical #stock #costreduction #announcement This is the hidden content, please Sign In or Sign Up This is the hidden content, please Sign In or Sign Up 0 Quote Link to comment https://hopzone.eu/forums/topic/246840-jpmorgan-says-buy-this-pharmaceutical-stock-following-cost-reduction-announcement/ Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.